{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-23-000083","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.254693+00:00","generated_at":"2026-06-11T12:13:40.880184+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Instil Bio Q2 2023 net loss $18.7M; cash $202.9M, ITIL-306 trial start 2H 2023","bullets":["Net loss of $18.7M ($0.14/share) vs. $59.0M loss in Q2 2022; R&D expenses down to $8.5M from $41.5M.","Cash, equivalents, restricted cash and marketable securities $202.9M as of June 30, 2023; cash runway expected beyond 2026.","ITIL-306 (CoStAR-TIL) clinical trial ITIL-306-202 anticipated to start in 2H 2023; initial data expected in 2024.","Manufacturing process improvements doubled CoStAR-TIL yield in final product from verification runs.","Restructuring and impairment charges of $1.0M in Q2 and $25.6M for six months ended June 30, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-23-000083","json":"https://secwatch.observer/filing/0001789769-23-000083.json","markdown":"https://secwatch.observer/filing/0001789769-23-000083.md","text":"https://secwatch.observer/filing/0001789769-23-000083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976923000083/0001789769-23-000083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976923000083/til-20230814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T12:13:40.880184+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"22f246ec734841fc366350a9b6c46813ddb86fa6","claim":"Instil Bio, Inc. reported second quarter 2023 results: net income $0.58 for the six months ended June 30, 2023, EPS $0.14 for the three months ended June 30, 2023.","evidence_excerpt":"Instil Bio, Inc. (the \"Company\") provided a corporate update and announced its financial results for the quarter ended June 30, 2023 in the press release attached hereto as Exhibit 99.1","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789769/000178976923000083/0001789769-23-000083-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Net income","value":"$0.58 for the six months ended June 30, 2023"},{"label":"EPS","value":"$0.14 for the three months ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}